Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. JS Silvestre, J Prous Methods and findings in experimental and clinical pharmacology 27 (5), 289-304, 2005 | 159 | 2005 |
Acute effects of ketamine in the holeboard, the elevated‐plus maze, and the social interaction test in Wistar rats JS Silvestre, R Nadal, M Pallares, N Ferre Depression and anxiety 5 (1), 29-33, 1997 | 133 | 1997 |
Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches. A Camins, M Pallas, JS Silvestre Methods and findings in experimental and clinical pharmacology 30 (1), 43-65, 2008 | 125 | 2008 |
Pleiotropic effects of statins and related pharmacological experimental approaches. M Alegret, JS Silvestre Methods and findings in experimental and clinical pharmacology 28 (9), 627-656, 2006 | 113 | 2006 |
Insulin analogues in the management of diabetes M Vazquez-Carrera, JS Silvestre Methods Find Exp Clin Pharmacol 26 (6), 445-461, 2004 | 74 | 2004 |
Effects of a range of dopamine receptor agonists and antagonists on ethanol intake in the rat JS Silvestre, MF O'Neill, AG Fernández, JM Palacios European journal of pharmacology 318 (2-3), 257-265, 1996 | 67 | 1996 |
Drug discovery targets: 5-HT6 receptor S Davies, JS Silvestre, X Guitart Drugs of the Future 30 (5), 2005 | 56 | 2005 |
Pagoclone-anxiolytic GABA-A/BZD site partial agonist LA Sorbera, PA Leeson, J Silvestre, J Castaner Drugs of the Future 26 (7), 651-657, 2001 | 53 | 2001 |
Effects of 5-HT4 receptor antagonists on rat behaviour in the elevated plus-maze test JS Silvestre, AG Fernández, JM Palacios European journal of pharmacology 309 (3), 219-222, 1996 | 53 | 1996 |
Effects of rolipram on the elevated plus-maze test in rats: a preliminary study JS Silvestre, AG Fernández, JM Palacios Journal of psychopharmacology 13 (3), 274-277, 1999 | 49 | 1999 |
Preliminary evidence for an involvement of the cholinergic system in the sedative effects of rolipram in rats JS Silvestre, AG Fernández, JM Palacios Pharmacology Biochemistry and Behavior 64 (1), 1-5, 1999 | 44 | 1999 |
Effects of ketamine, a noncompetitive NMDA antagonist, on the acquisition of the lever-press response in rats MA Pallares, RA Nadal, JS Silvestre, NS Ferre Physiology & behavior 57 (2), 389-392, 1995 | 40 | 1995 |
Opposite effects of ethanol and ketamine in the elevated plus-maze test in Wistar rats undergoing a chronic oral voluntary consumption procedure JS Silvestre, M Pallarés, R Nadal, N Ferré Journal of Psychopharmacology 16 (4), 305-312, 2002 | 39 | 2002 |
Vilazodone hydrochloride LA Sorbera, X Rabasseda, J Silvestre, J Castaner Drugs of the Future 26 (3), 2001 | 37 | 2001 |
Acyl coenzyme A: cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs. M Alegret, G Llaverias, JS Silvestre Methods and findings in experimental and clinical pharmacology 26 (7), 563-586, 2004 | 36 | 2004 |
Etoricoxib LA Sorbera, RM Castaner, J Silvestre, J Castaner Drugs of the Future 26 (4), 2001 | 36 | 2001 |
Eplerenone X Rabasseda, J Silvestre, J Castaner Drugs of the Future 24 (5), 1999 | 35 | 1999 |
Aprepitant and L-758298: antiemetic, antidepressant, tachykinin NK1 antagonist LA Sorbera, J Castaner, M Bayes, J Silvestre Drugs of the Future 27 (3), 211-222, 2002 | 34 | 2002 |
Comparative evaluation of hERG potassium channel blockade by antipsychotics. JS Silvestre, JR Prous Methods and findings in experimental and clinical pharmacology 29 (7), 457-466, 2007 | 33 | 2007 |
Experimental approaches to study PPAR gamma agonists as antidiabetic drugs M Vazquez, JS Silvestre, JR Prous Methods Find Exp Clin Pharmacol 24 (8), 515-523, 2002 | 32 | 2002 |